[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monoterpenoid-zinc-tetra-ascorbo-camphorate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monoterpenoid-zinc-tetra-ascorbo-camphorate":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100567781","phase-1-tolerance-and-effectiveness-of-c14-on-hpv-infection-100567781",false,"NCT06672653","Tolerance and Effectiveness of C14 on HPV Infection","PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit","PREPAP","Inclusion Criteria:\n\n* sexually-active women\n* aged at least 30 years old\n* who will give their informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant\n* breastfeeding and post-partum women will not be accepted in the study.\n* previous cervical surgery, medical history of any severe diseases, intake or application of other antivirals\n* known or suspected allergic or adverse response to the investigational product or its components\n* women who are unable to follow the study protocol.","FEMALE","30 Years","65 Years",{"count":21,"type":22},66,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug.\n\nThe aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows:\n\nDoes C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do participants experience when taking C14? Researchers will compare C14 to a placebo (a similar substance that contains no drug) to see if C14 is effective in reducing genital C14 viral load and in treating low-grade dysplastic lesions of the cervix.\n\nParticipants will\n\nreceive four monthly treatments (5ml of C14 dissolved in distilled water administered twice daily \\[morning and evening\\] for seven days via vaginal syringe during the follicular phase) of C14 or placebo for 4 months and visit the clinic once every 2 weeks for examinations and tests. They will keep a diary of their symptoms and the number of times they keep the hospital appointment.",[29,30,31,32,33,34,35],"HPV-induced Cancers","HPV Infections","HIV","Cervical Cancers","Trial","C14","Monoterpenoid Zinc Tetra-ascorbo-camphorate","NOT_YET_RECRUITING","2024-11-01",{"date":39,"type":40},"2024-11-04","ACTUAL",{"date":42,"type":22},"2024-11-15",{"date":44,"type":22},"2025-07-15",{"name":46,"class":47},"MGB Pharma","INDUSTRY"]